Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A double blind, placebo controlled trial evaluating pegylated recombinant human megakaryocyte growth and development factor (MGDF) as an adjunct to induction and consolidation therapy in patients with acute myeloid leukemia (AML)

A double blind, placebo controlled trial evaluating pegylated recombinant human megakaryocyte growth and development factor (MGDF) as an adjunct to induction and consolidation therapy in patients with acute myeloid leukemia (AML). ASH. 1998; 313 (#1283).


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.